Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease.
Psaty
B M
BM
Department of Medicine, University of Washington, Seattle 98101, USA.
Weiss
N S
NS
Furberg
C D
CD
Koepsell
T D
TD
Siscovick
D S
DS
Rosendaal
F R
FR
Smith
N L
NL
Heckbert
S R
SR
Kaplan
R C
RC
Lin
D
D
Fleming
T R
TR
Wagner
E H
EH
D015415:Biomarkers; D002317:Cardiovascular Agents / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000517:prevention & control*; D002986:Clinical Trials as Topic; D017277:Drug Approval; D006801:Humans; D012306:Risk; D012307:Risk Factors; D016896:Treatment Outcome; D014481:United States; D014486:United States Food and Drug Administration
D015415:Biomarkers; D002317:Cardiovascular Agents